2.8亿！真迈生物完成C+轮融资

Core Insights - The article highlights the recent financing activities and product developments of Zhenmai Biotechnology, emphasizing its role in the gene sequencing industry and its upcoming participation in global medical technology conferences [1][9]. Financing Activities - On May 28, 2025, Zhenmai Biotechnology announced the completion of a C+ round financing amounting to 280 million yuan, led by Shengxiang Biology, Jinyu Medical, and other investment institutions. The funds will be used for commercial ecosystem construction and global expansion [1][9]. - In August 2023, the company completed a C round of financing, with specific amounts undisclosed, aimed at core technology product development and medical device qualification applications [9]. Product Development - Zhenmai Biotechnology, established in 2012 and headquartered in Shenzhen, China, specializes in high-tech gene sequencing instruments and related reagents. The company offers advanced gene sequencing solutions for global life science research and clinical diagnostics [5]. - The company possesses the world's highest throughput desktop gene sequencer, SURFSeq 5000, with a capacity of 2.2 Tb/run, and the ultra-high throughput sequencer, SURFSeq Q, which has a daily output of 9 Tb [5]. - In September 2024, GenoLab M Dx was approved as the first domestically produced high-throughput gene sequencer using the "reversible terminator sequencing method" [5][7]. - In April 2025, FASTASeq 300 Dx, which offers advantages in speed, cost, and sample flexibility, received approval [5][7]. Industry Events - The article lists upcoming global medical technology conferences organized by Siyu, including the first Global Aesthetic Technology Conference on June 12, 2025, the second Global Medical Technology Conference on July 17, 2025, and the third Global Surgical Robot Conference on September 4-5, 2025 [1][8].